Tie Hong-Tao, Su Guang-Zhu, He Kun, Liang Shao-Rong, Yuan Hao-Wei, Mou Jun-Huan
Department of Pharmacy, Jinan Central Hospital, Jinan 250013, Shandong, China.
BMC Anesthesiol. 2014 Mar 3;14:12. doi: 10.1186/1471-2253-14-12.
Shivering is a very common complication in the postanesthesia period. Increasing studies have reported ondansetron may be effective in prevention of postanesthesia shivering (PAS). However, the results remained controversial; hence we conducted a meta-analysis of randomized controlled trials to evaluate the efficacy and safety of ondansetron on the prevention of postanesthesia shivering.
PubMed and Embase databases were searched to identify the eligible randomized controlled trials assessing the effect of ondansetron on the prevention of PAS. Results were expressed as risk ratios (RRs) with accompanying 95% confidence intervals (CIs). The meta-analysis was performed with fixed-effect model or random-effect model according to the heterogeneity.
Six trials including 533 subjects were included. Compared with placebo, ondansetron was associated with a significant reduction of PAS (RR 0.43, 95% CI, 0.27-0.70), without an increased risk of bradycardia (RR 0.37, 95% CI, 0.12-1.15). Compared with meperidine, no difference was observed in the incidence of PAS (RR 0.68, 95% CI, 0.39-1.19) and bradycardia (RR 2.0, 95% CI, 0.38-10.64).
Ondansetron has a preventive effect on PAS without a paralleled side effect of bradycardia.
寒战是麻醉后时期非常常见的并发症。越来越多的研究报道昂丹司琼可能对预防麻醉后寒战(PAS)有效。然而,结果仍存在争议;因此,我们进行了一项随机对照试验的荟萃分析,以评估昂丹司琼预防麻醉后寒战的疗效和安全性。
检索PubMed和Embase数据库,以确定评估昂丹司琼预防PAS效果的合格随机对照试验。结果以风险比(RRs)及伴随的95%置信区间(CIs)表示。根据异质性,采用固定效应模型或随机效应模型进行荟萃分析。
纳入6项试验,共533名受试者。与安慰剂相比,昂丹司琼与PAS的显著降低相关(RR 0.43,95%CI,0.27 - 0.70),且心动过缓风险未增加(RR 0.37,95%CI,0.12 - 1.15)。与哌替啶相比,PAS发生率(RR 0.68,95%CI,0.39 - 1.19)和心动过缓发生率(RR 2.0,95%CI,0.38 - 10.64)均未观察到差异。
昂丹司琼对PAS有预防作用,且无心动过缓的平行副作用。